Electroacupuncture Treatment For Delayed Chemotherapy-induced Nausea And Emesis
电针治疗延迟化疗引起的恶心和呕吐
基本信息
- 批准号:7592495
- 负责人:
- 金额:$ 97.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Acupuncture procedureAcuteAdrenal Cortex HormonesAdverse effectsAffectAgeAnteriorAntiemeticsBiological MarkersBlindedChildhood Solid NeoplasmClinical ManagementDiagnosisDoseElectroacupunctureEndocrineEnrollmentEwings sarcomaGerm cell tumorGrowthHourImmune systemImmunologicsInfectionLeftMetabolicMuscleNauseaNausea and VomitingNeedlesNeuroblastomaPatientsQuality of lifeRandomizedRecurrenceReportingRiskSolid NeoplasmStressStudy SubjectTherapeuticTreatment ProtocolsVomitingWeight GainWithdrawalWristchemotherapydaydesignimprovedosteosarcomasarcomastressorsymptom managementsynovial sarcomatreatment duration
项目摘要
Acupuncture and electroacupuncture at the P6 point in the wrist and the St 36 point in the anterior tibialis muscle have been been reported to be effective in reducing nausea and emesis occurring acutely (less than 24 hours) after chemotherapy. Although acute chemotherapy-induced nausea and emesis can be also be effectively treated with contemporary pharmacologic anti-emetic regimens, delayed nausea (more than 24 hours to 5 days) after chemotherapy continues to be a clinical management challenge. Patients diagnosed with pediatric solid tumors can be successfully treated using a comprehensive approach that includes highly emetogenic multi-agent chemotherapy. Delayed nausea is often managed by recurrent administration of high dose corticosteroids, with suboptimal therapeutic benefit and frequent undesirable side effects, such as weight gain, growth retardation and increased risk for infections. Recurrent or delayed nausea, in addition to its negative effect on Quality of Life (QOL), may constitute a state of stress for the affected patient, contributing to adverse endocrine, metabolic and immunologic sequelae. Mechanisms of activity of acupuncture in the treatment of acute nausea and emesis have not been clarified. We have initiated a study to determine whether electroacupuncture is effective in the treatment of chemotherapy-induced delayed nausea and emesis in patients with pediatric solid tumors, resulting in improved management of these symptoms and enhanced QOL. We also aim to identify whether acupuncture reduces the stressor state of these chemotherapy-treated patients, reversing its negative effects on the neuro-endocrine and immune systems. Using a randomized, blinded design with control, sham needling, we shall study a total of 52 chemotherapy-naive patients with pediatric solid tumors, age 5-35 years, who will be enrolled for one electroacupuncture treatment period of 7 days during the first chemotherapy cycle, followed by one observation cycle of chemotherapy without acupuncture. 12 study subjects have been enrolled to date: Ewings sarcoma (6), osteosarcoma (2), synovial sarcoma, germ cell tumor, neuroblastoma and other sarcoma (one each respectively). Nine of the 12 completed the study; 2 subjects left the study during cycle 1 (change in diagnosis 1, voluntary withdrawal 1), one subject voluntarily withdrew from the study after cycle 1.
据报道,腕部肌肉的P6点的针灸和电针刺据报道,胫骨前肌的ST 36点有效减少恶心,化学疗法后急性(小于24小时)发生呕吐。尽管急性化学疗法引起的恶心和呕吐也可以通过当代药理抗雌激素方案有效治疗,但化学疗法后的恶心延迟(超过24小时至5天)继续是临床管理挑战。可以使用综合方法成功治疗被诊断为小儿实体瘤的患者,该方法包括高度突出的多药化学疗法。延迟的恶心通常通过反复施用高剂量皮质类固醇,具有次优的治疗益处和频繁的不良副作用,例如体重增加,增长迟缓和感染风险增加。除了对生活质量的负面影响(QOL)外,复发性或延迟的恶心还可能构成受影响患者的压力状态,从而导致内分泌,代谢和免疫后遗症。尚未澄清针灸治疗中针灸活性的机制。我们已经开始了一项研究,以确定电针作是否有效治疗儿科实体瘤患者的化学疗法引起的延迟恶心和屈服,从而改善了这些症状的治疗和增强的QOL。我们还旨在确定针灸是否减少了这些化学疗法治疗的患者的压力源状态,从而扭转了其对神经内分泌和免疫系统的负面影响。使用带有对照,假针的随机盲设计,我们将研究52例儿童固体瘤患者,年龄为5-35岁,他们将在第一次化学疗法期间招募7天的7天电针治疗期周期,然后是一个无针灸的化学疗法观察周期。迄今为止,已有12个研究对象已经入学:Ewings肉瘤(6),骨肉瘤(2),滑膜肉瘤,生殖细胞肿瘤,神经母细胞瘤和其他肉瘤(分别分别为一个)。这12个完成了这项研究; 2个受试者在周期1(诊断1的变化,自愿戒断1的变化)中离开了研究,一名受试者自愿退出了第1周期之后的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Patrick J Mansky其他文献
Patrick J Mansky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Patrick J Mansky', 18)}}的其他基金
Electroacupuncture--Delayed Chemotherapy Nausea/Emesis
电针--延迟化疗恶心/呕吐
- 批准号:
6678550 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
Mistletoe Extract--PK, PD, & Safety of Gemcitabine in CA
槲寄生提取物--PK、PD、
- 批准号:
6678552 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
A Phase I Study of Mistletoe Extract on PK, PD, and Safety of Gemcitabine in CA
槲寄生提取物对吉西他滨在 CA 中的 PK、PD 和安全性的 I 期研究
- 批准号:
7732850 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
A Phase I Study of Mistletoe Extract on PK, PD, and Safety of Gemcitabine in CA
槲寄生提取物对吉西他滨在 CA 中的 PK、PD 和安全性的 I 期研究
- 批准号:
7592496 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
A Phase I Study of Mistletoe Extract on PK, PD, and Safe
槲寄生提取物的 PK、PD 和安全性的 I 期研究
- 批准号:
6814577 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
Electroacupuncture Treatment For Delayed Chemotherapy-induced Nausea And Emesis
电针治疗延迟化疗引起的恶心和呕吐
- 批准号:
7732849 - 财政年份:
- 资助金额:
$ 97.4万 - 项目类别:
相似国自然基金
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
- 批准号:82300764
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACSS2介导的乙酰辅酶a合成在巨噬细胞组蛋白乙酰化及急性肺损伤发病中的作用机制研究
- 批准号:82370084
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
- 批准号:82370175
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Achieving Sustained Control of Inflammation to Prevent Post-Traumatic Osteoarthritis (PTOA)
实现炎症的持续控制以预防创伤后骨关节炎 (PTOA)
- 批准号:
10641225 - 财政年份:2023
- 资助金额:
$ 97.4万 - 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 97.4万 - 项目类别:
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 97.4万 - 项目类别:
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD
一种吸入性微生物组靶向生物治疗药物,用于治疗慢性阻塞性肺病
- 批准号:
10600887 - 财政年份:2023
- 资助金额:
$ 97.4万 - 项目类别: